These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30653702)

  • 1. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder.
    Wang B; Xie S; Bi J; Liu Z; Zeng H; Huang H; Xue M; He Z; Yang M; Yu H; Huang J; Lin T
    Histopathology; 2019 Sep; 75(3):354-364. PubMed ID: 30653702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
    Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
    World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival.
    Hou W; Xue M; Shi J; Yang M; Zhong W; Fan X; Zeng H; Lai Y; Huang J; Wang B; Lin T
    Urol Oncol; 2020 Aug; 38(8):685.e1-685.e10. PubMed ID: 32409198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Liu K; Zhao K; Wang L; Sun E
    Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer.
    Zhang Q; Hao C; Cheng G; Wang L; Wang X; Li C; Qiu J; Ding K
    Int J Clin Exp Pathol; 2015; 8(9):11510-6. PubMed ID: 26617883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.
    Lillesand M; Kvikstad V; Mangrud OM; Gudlaugsson E; van Diermen-Hidle B; Skaland I; Baak JPA; Janssen EAM
    PLoS One; 2020; 15(6):e0233676. PubMed ID: 32484812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
    Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
    BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of preoperative serum albumin-globulin ratio for high-grade bladder urothelial carcinoma treated with radical cystectomy: A propensity score-matched analysis.
    Liu Z; Huang H; Li S; Yu W; Li W; Jin J; Li X; Xing J
    J Cancer Res Ther; 2017; 13(5):837-843. PubMed ID: 29237914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.
    Marks P; Gild P; Soave A; Janisch F; Minner S; Engel O; Vetterlein MW; Shariat SF; Sauter G; Dahlem R; Fisch M; Rink M
    Surg Oncol; 2019 Mar; 28():208-213. PubMed ID: 30851902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
    Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
    Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
    Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
    Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
    Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
    Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.